Leucine-rich repeat kinase 2 (LRRK2) is a recently identified gene that, when mutated at specific locations, results in the onset of parkinsonian symptoms with clinical features indistinguishable from idiopathic Parkinson's disease. Based on structural and domain analysis, LRRK2 is predicted to function as a stressresponsive protein scaffold mediating the regulation of mitogen activating protein kinase (MAPK) pathways. Consistent with this notion, our results supported the notion that expression of wild-type LRRK2 but not Y1699C or G2019S mutants enhanced the tolerance of HEK293 and SH-SY5Y cells towards H 2 O 2 -induced oxidative stress. This increase in stress tolerance was dependent on the presence of the kinase domain of the LRRK2 gene and manifested through the activation of the ERK pathway. Collectively, our results indicated that cells expressing LRRK2 mutants suffer a loss of protection normally derived from wild-type LRRK2, making them more vulnerable to oxidative stress.
Introduction
Leucine-rich repeat kinase 2 (LRRK2), a member of the ROCO protein family, is a recently identified gene whose mutants have been linked to the onset of parkinsonian symptoms (Haugarvoll and Wszolek, 2006; Klein and Schlossmacher, 2006; Olanow, 2007; Whaley et al., 2006) . Sequence domain analysis of this gene has revealed that the 285 kDa protein for which it encodes comprises ROC, COR, kinase, and WD40 domains, in that order, with the ROC domain beginning after the first 1000 amino acids (Jain et al., 2005; West et al., 2005) . The ROC domain, with its GDP/GTP binding motif has been shown to be capable of altering the kinase activity of LRRK1, a paralog of LRRK2 (Korr et al., 2006) . To date, the impact of these mutations on wild-type LRRK2 is yet unclear.
Expressions of LRRK2 mutant genes, such as Y1699C and R1441C, result in a loss of basal cell viability in SHSY5Y cells (Greggio et al., 2006; West et al., 2005) demonstrating their innate toxicity. Since G2019S and I2020T mutants show higher kinase activities than wild-type LRRK2, it has been speculated that alteration of kinase activity is involved in the manifestation of parkinsonian symptoms caused by LRRK2 mutations (Bialecka et al., 2005; Tomiyama et al., 2006; West et al., 2005) . However, further investigation showed that different LRRK2 mutants have different inherent kinase activity based on an auto-phosphorylation assay. Indeed, some mutants have lower kinase activity than the wildtype counterpart. For example, it has been shown that the Y1699C mutant has lower kinase activity than wild-type LRRK2 and yet has the highest propensity to elicit the formation of protein aggregates (Greggio et al., 2006) . Therefore, it is uncertain whether changes in kinase activities among the LRRK2 mutants contribute to the cause of pathology.
Phylogenetic analysis of the LRRK2 kinase domain has revealed sequence similarity to the receptor interaction protein (RIP) protein family as well as mixed lineage kinases (Meylan and Tschopp, 2005; Xu et al., 2001) , raising the possibility of parallel functions among these kinases. In fact, Meylan and Tschopp (2005) have termed LRRK1 and LRRK2 as RIP6 and RIP7 respectively. Both of these kinase families participate in the signaling events in response to cellular stresses caused by various stimuli (Gloeckner et al., 2006) . Therefore, it is likely that LRRK2 wild-type gene product is also involved in stress-induced signaling events leading to cell death.
In this study, our main objective was to investigate whether LRRK2 is involved in a stress-induced signaling cascade mediating cell death and, if so, to identify differential responses derived from LRRK2 wildtype, Y1699C and G2019S mutant genes in these events. Our results suggest that expression of LRRK2 wild-type or Y1699C mutant genes in HEK293 cells suppressed basal levels of activated ERK but not JNK, independent of its kinase domain. Moreover, the presence of LRRK2 wild-type gene product but not Y1699C or G2019S mutant gene product conferred protection against H 2 O 2 -induced cell death through activation of the ERK pathway mediated by its kinase domain in HEK293 and SH-SY5Y cells. Therefore, based on our results, this multifunctional domain LRRK2 gene is able to affect the activation of the ERK pathway. 
